| 产品名称： | ME361-S2a ME361S2a |
|---|---|
| 商品货号： | TS211484 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain： | Strain:xa0 BALB/c (B cell); BALB/c (myeloma) |
| Applications： | The antibody reacts with GD2 and GD3 gangliosides. It reacts preferentially with the GD2 and is largely unreactive with other gangliosides. It may be useful for diagnosis and therapy of human melanoma. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with P3X63Ag8.653 myeloma cells. |
| Clinical Data： | It may be useful for diagnosis and therapy of human melanoma. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against GD2 and GD3 gangliosides |
| Cellular Products： | immunoglobulin; monoclonal antibody; against GD2 and GD3 gangliosides |
| Comments： | Animals were immunized with the SK MEL 23 human melanoma cells line. Spleen cells were fused with P3X63Ag8.653 myeloma cells. The antibody reacts with GD2 and GD3 gangliosides. It reacts preferentially with the GD2 and is largely unreactive with other gangliosides. It may be useful for diagnosis and therapy of human melanoma. This line is an isotype switch variant of ME361 (see ATCC HB-9325). |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | culture medium, 85%; fetal bovine serum, 10%; DMSO, 5% |
| Culture Conditions： | Temperature: 37.0°C |
| Isotype： | IgG2a |
| Name of Depositor： | Wistar Institute |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Thurin J, et al. Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies. US Patent 4,849,509 dated Jul 18 1989 Thurin J, et al. GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression. FEBS Lett. 208: 17-22, 1986. PubMed: 3533633 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | ME361-S2a ME361S2a |
|---|---|
| 商品货号： | TS211484 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain： | Strain:xa0 BALB/c (B cell); BALB/c (myeloma) |
| Applications： | The antibody reacts with GD2 and GD3 gangliosides. It reacts preferentially with the GD2 and is largely unreactive with other gangliosides. It may be useful for diagnosis and therapy of human melanoma. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with P3X63Ag8.653 myeloma cells. |
| Clinical Data： | It may be useful for diagnosis and therapy of human melanoma. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against GD2 and GD3 gangliosides |
| Cellular Products： | immunoglobulin; monoclonal antibody; against GD2 and GD3 gangliosides |
| Comments： | Animals were immunized with the SK MEL 23 human melanoma cells line. Spleen cells were fused with P3X63Ag8.653 myeloma cells. The antibody reacts with GD2 and GD3 gangliosides. It reacts preferentially with the GD2 and is largely unreactive with other gangliosides. It may be useful for diagnosis and therapy of human melanoma. This line is an isotype switch variant of ME361 (see ATCC HB-9325). |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | culture medium, 85%; fetal bovine serum, 10%; DMSO, 5% |
| Culture Conditions： | Temperature: 37.0°C |
| Isotype： | IgG2a |
| Name of Depositor： | Wistar Institute |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Thurin J, et al. Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies. US Patent 4,849,509 dated Jul 18 1989 Thurin J, et al. GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression. FEBS Lett. 208: 17-22, 1986. PubMed: 3533633 |
